Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective - LC-MS in Drug Bioanalysis - page 222

Fig. 2 Principal tamoxifen metabolic pathways of clinical interest. Abbreviations: Tam (Tamoxifen),
N -D-Tam ( N -desmethyl-tamoxifen), N -DD-Tam ( N , N -didesmethyl-tamoxifen), 4-OH-Tam
(4-Hydroxy-Tamoxifen), 4¢ -OH-Tam (4 ¢-Hydroxy-tamoxifen), Tam-NO (Tamoxifen- N -oxide),
Endoxifen (4-Hydroxy- N -desmethyl-tamoxifen), 4 ¢ -OH- N -D-Tam (4 ¢ -Hydroxy- N -desmethyl-
tamoxifen), Tam- N + -Gluc (Tamoxifen- N + -glucuronide), Tam-4- O -Gluc (Tamoxifen-4- O -glucuronide),
N -D-Tam-4- O -Gluc ( N -desmethyl-tamoxifen-4- O -glucuronide), Tam-4- O -SO 3 H (Tamoxifen-4- O -
sulfate), N -D-Tam-4- O -SO 3 H ( N -desmethyl-tamoxifen-4- O -sulfate)